SUMMARY The Starr-Edwards Model 6000 mitral valve was the first successful mitral prosthesis. A fifteen year follow-up of 110 patients undergoing isolated mitral valve replacement with this prosthesis from 1960 to 1966 is presented. There were 22 (20%) operative and 37 (42%) late deaths at a mean of 8.6 years postoperatively. Preoperative variables leading to late death and throm-THE STARR-EDWARDS MODEL 6000 mitral valve, introduced in 1960,1 was the first artificial valve prosthesis to enjoy widespread clinical use. The basic design incorporated a silastic ball in a cage of Stellite-2 1 with a cloth sewing ring. The outflow and inflow faces were metallic and the struts rather thick and elongated compared to modern designs. Due to problems with thromboembolism, the 6000 mitral valve was superceded by the Model 6120 in February 1966. Since then, additional modifications have emerged, and have been the subject of several reviews.2D espite advances in valve design, our interest in the 6000 mitral valve remains strong for its historical significance, as well as for the ongoing care of those patients who continue to rely on this prosthesis. These patients represent the longest follow-up available on any prosthetic cardiac device and provide a baseline against which the biocompatibility of all subsequent modifications can be judged. For these reasons, a retrospective review of the clinical course of these patients over the past 15 years was initiated. From August 25, 1960 to February 25, 1966 figure 1 . For comparison, a survival curve for an age and sex-matched group from a normal population is included in figure I (based on 1960-61 U.S. Life Tables).
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Materials and Methods
Statistical analysis of preoperative and valve-related variables listed in table 1, as well as implant date and size, revealed age greater than 50 years (P <0.02) and the presence of aortic stenosis (P < 0.05) to be significant predictors of late mortality. The implant date and size, mean duration of symptoms, sex, the nature of the mitral lesion, and the presence of aortic regurgitation were not significant. In regard to catheterization data, mean pulmonary artery pressure greater than 40, a mean left atrial pressure greater than 25, a cardiac index less than 2.5, and a pulmonary vascular resistance greater than 2.5 units were not significant predictors of late mortality. It is in the area of thromboembolism that valve design is crucial. A 40-50% incidence of emboli at 5 years among operative survivors of Model 6000 valve replacement has been reported by Levine et al. 5 and Barnhorst et al. 6 Our data indicate that only 20% of patients can be expected to be embolus-free at 15 years. It is of interest to note, however, that the incidence of emboli does tend to level off with time, a fact also suggested by the data in an earlier follow-up study by Levine et al.5 It would seem that some patients are more likely than others to generate thromboemboli, corroborated by the fact that preoperative thromboembolism in this series was a significant predictor of postoperative thromboembolism, independent of atrial fibrillation. The removal by attrition of these patients would account for the decreasing incidence of emboli with time. This problem has been examined with mitral valves of more recent design, where the rate of embolism seems to remain constant. 4 This discrepancy might well relate to a unique patient-valve interaction related to the design of the 6000 mitral valve. Conversely, the low rate of embolism with current valves ffiight suggest longer follow-up periods are needed to settle this issue. Figure 2 demonstrates the improved thromboembolic performance that has been achieved with later valve models, principally by extending the cloth covering to the verge of the orifice (Model 6120) and, ultimately, the entire cage. A more recent model provides metallic tracks on the inner surface of the struts to avoid cloth wear (Model 6400). We would estimate that there are approximately 5000 patients world-wide currently relying on the Model 6000 valve. While the long-term biocompatibility and mechanical durability of the Model 6000 valve have been proven beyond doubt, the high rate of thromboembolism compared with current alternatives, and the present low operative mortality, raises the question whether or not patients with the 6000 mitral valve who are good operative risks should be subjected to elective re-replacement. In view of the markedly decreased incidence of emboli with time, we feel that these patients now surviving with this valve model in place generally represent a naturally selected subgroup whose current risk of thromboembolism is quite low. This does not apply to patients with repeated thromboembolic episodes. In these patients, elective re-replacement with a valve model of more recent design should be seriously considered.
